Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:21:42 EST Wed 31 Dec 2025
Enter Symbol
or Name
USA
CA



Q:SGMO - SANGAMO THERAPEUTICS INC - https://www.sangamo.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SGMO - Q1.00.4116·0.441.50.42-0.0073-1.74,916.11,8514,0470.4273  0.43  0.4061.51  0.384618:48:13Dec 1815 min RT 2¢

Recent Trades - Last 10 of 4047
Time ETExPriceChangeVolume
18:48:13Q0.4116-0.01574,000
18:46:54Q0.4116-0.01573,000
18:46:25Q0.4116-0.01573,000
18:45:42Q0.4116-0.01571,600
18:45:42Q0.4116-0.01571,400
18:45:10Q0.4116-0.01571
18:44:08Q0.4116-0.01572,000
18:43:29Q0.4116-0.01572,000
18:42:47Q0.4116-0.01572,000
18:42:10Q0.4116-0.01572,000

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-12-18 08:05U:SGMONews ReleaseSangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
2025-12-02 08:05U:SGMONews ReleaseSangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
2025-11-21 08:05U:SGMONews ReleaseSangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
2025-11-06 08:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
2025-10-30 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Third Quarter 2025 Earnings Call
2025-09-04 08:05U:SGMONews ReleaseSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
2025-08-07 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results
2025-07-31 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Second Quarter 2025 Earnings Call
2025-06-24 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
2025-05-12 18:26U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
2025-05-12 18:23U:SGMONews ReleaseSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
2025-05-12 16:00U:SGMONews ReleaseSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
2025-05-06 16:35U:SGMONews ReleaseSangamo Therapeutics Announces First Quarter 2025 Earnings Call
2025-05-06 08:30U:SGMONews ReleaseSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
2025-04-28 16:31U:SGMONews ReleaseSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2025-04-03 16:01U:SGMONews ReleaseSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
2025-03-17 16:01U:SGMONews ReleaseSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
2025-03-06 16:05U:SGMONews ReleaseSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
2025-02-06 08:05U:SGMONews ReleaseSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile